Pharmadrug Inc
Pharmadrug Inc. operates as a specialty pharmaceutical company. The company focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs. It also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs fo… Read more
Pharmadrug Inc (LMLLF) - Total Liabilities
Latest total liabilities as of September 2025: $2.07 Million USD
Based on the latest financial reports, Pharmadrug Inc (LMLLF) has total liabilities worth $2.07 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharmadrug Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Pharmadrug Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pharmadrug Inc Competitors by Total Liabilities
The table below lists competitors of Pharmadrug Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OSHKOSH
BE:OK3
|
Germany | €5.77 Billion |
|
SRIVARU Holding Limited
PINK:SVUHF
|
USA | $1.54 Million |
|
HYUNGJI INNOVATION & CREATIVE Co.Ltd
KQ:011080
|
Korea | ₩25.13 Billion |
|
Entheon Biomedical Corp
OTCQB:ENTBF
|
USA | $16.12K |
|
Tie Holding NV
F:TJH7
|
Germany | €2.87 Million |
|
d'Alba Global
KO:483650
|
Korea | ₩54.09 Billion |
|
Brigadier Gold Limited
PINK:BGADF
|
USA | $872.30K |
Liability Composition Analysis (2012–2024)
This chart breaks down Pharmadrug Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharmadrug Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharmadrug Inc (2012–2024)
The table below shows the annual total liabilities of Pharmadrug Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.96 Million | -26.60% |
| 2023-12-31 | $2.66 Million | -18.68% |
| 2022-12-31 | $3.28 Million | +23.42% |
| 2021-12-31 | $2.66 Million | -14.83% |
| 2020-12-31 | $3.12 Million | -47.34% |
| 2019-12-31 | $5.92 Million | +281.31% |
| 2018-12-31 | $1.55 Million | +7242.44% |
| 2017-12-31 | $21.15K | -70.63% |
| 2016-12-31 | $72.00K | -1.02% |
| 2015-12-31 | $72.74K | -79.40% |
| 2014-12-31 | $353.05K | +188.22% |
| 2013-12-31 | $122.49K | +392.57% |
| 2012-12-31 | $24.87K | -- |